Education
About Us
Working with TipRanks
Follow Us
Zynex (ZYXI)
NASDAQ:ZYXI
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.24Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 11, 2025
|% Change Since: -67.86%
|Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted growth in revenue per sales rep, positive trial results for the NiCO pulse oximeter, and significant cost savings. However, major challenges included the Tricare payment suspension impacting a substantial revenue portion, a reported net loss for Q4, and decreased device revenue. The lack of clear guidance for 2025 due to these uncertainties also weighed negatively.Company Guidance
During the Zynex Fourth Quarter 2024 Earnings Conference Call, the company provided guidance marked by both optimism and caution. Zynex reported a 4% increase in revenue for 2024 and a 16% growth in orders, but faced challenges due to a temporary suspension of payments by Tricare, which accounts for 20% to 25% of their revenue. This has impacted their ability to provide full 2025 guidance. The company implemented a 15% staff reduction in the corporate office, resulting in annual savings of approximately $35 million, and adjusted its sales force, reducing the number of sales reps from 475 to 330 while increasing revenue per rep by 22% to $490,000. Zynex projects $30 million in revenue for Q1 2025, with an anticipated net loss between $9 million and $10 million. They are also on the brink of FDA submission for their NiCO pulse oximeter, aimed at entering a multi-billion dollar market, and remain focused on diversifying products and revenue streams.Revenue Growth and Diversification
Revenue increased 4% in 2024, with order growth at 16%. There was also a 22% increase in revenue per sales rep, reaching $490,000 on average.
NiCO Pulse Oximeter Development
Positive results from human trials at Duke University and UCSF. FDA 510(k) submission anticipated soon, potentially allowing entry into a multi-billion dollar market.
Cost Savings
Cost restructuring initiatives expected to save approximately $35 million annually, with staff reductions of 15% primarily in corporate roles.
Strong Cash Position
End-of-year cash balance of $39.6 million, a 5% increase from Q3, with positive cash flows from operations for the year.
---
ZYXI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZYXI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 11, 2025 | $7.00 | $3.41 | -51.29% |
| Oct 24, 2024 | $8.59 | $9.12 | +6.17% |
| Jul 25, 2024 | $10.19 | $8.93 | -12.37% |
| Apr 30, 2024 | $10.97 | $11.77 | +7.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zynex (ZYXI) report earnings?
Zynex (ZYXI) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Zynex (ZYXI) earnings time?
Zynex (ZYXI) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZYXI EPS forecast?
ZYXI EPS forecast for the fiscal quarter 2025 (Q1) is -0.24.
---